Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Martina S.J. McDermott(University of California, Los Angeles), Dennis J. Slamon(University of California, Los Angeles)
Cited by 48
Related Papers
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
|Breast Cancer Research|2020|155
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
|Molecular Cancer|2014|42
Role for polo-like kinase 4 in mediation of cytokinesis
|Proceedings of the National Academy of Sciences|2019|40